Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
|Articles|April 12, 2012
ALL TOPICS Navigation
Author(s)OBGYN.net Staff
Advertisement
Adhesions
Breast Health and Breast Care
Complementary & Alternative Medicine
Contraception
Dense Breasts
Endometriosis
Fetal Monitoring
Fibroids
Gestational Diabetes
Gynecologic Oncology
HPV
Hysterectomy
IVF
Incontinence
Infertility
Integrative Medicine
Laparoscopy and Hysteroscopy
Laparoscopy
Malpractice
Menopause
Mesothelioma
Nurses
Nursing
Ob/Gyn EHR
Osteoporosis
Pelvic Pain
Polycystic Ovary Syndrome
Postpartum Depression
Pregnancy and Birth
Premenstrual Syndrome and Premenstrual Dysphoric Disorder
Prenatal Genetic Testing
Residency
Sex-related Issues
Surgical Gynecology
Technology
Urogynecology
Uterine Polyps
Weight Management
Young Women
Advertisement
Related to this article
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.
Chrisandra Shufelt, MD, on why menopause is a window for cardiovascular prevention and the risk factors OB/GYNs should assess.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Rhonda Voskuhl, MD, on a case series in which estriol and progesterone improved self-reported cognition in menopausal women at 12 months.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
FDA removes boxed warnings from 3 more menopausal hormone therapy products
3
Chrisandra Shufelt, MD, on cardiovascular risk assessment and menopause care
4
Matthew Nudy, MD, on estrogen and the cardiovascular system
5